





Von Emster, Kurt - The Wall Street Transcript













































 





































Kurt  Von Emster
KURT VON EMSTER joined MPM Capital, LP, in November 2000 to extend their
healthcare investment presence into the public markets. He is a General
Partner of the MPM BioEquities Fund and manages several funds for MPM
Advisors. He spent 11 years with Franklin Templeton Group as a Vice
President and Portfolio Manager. At Franklin, Mr. von Emster managed
over $2 billion in health and biotech funds, including the Franklin
Biotechnology Discovery Fund and the Franklin Global Health Care Fund.
Mr. von Emster holds the Chartered Financial Analyst designation, is a
member of the Association for Investment Management and Research, and is
a member of the Security Analysts of San Francisco. Mr. von Emster
earned a degree from the University of California Santa Barbara in
Business and Economics.
Related Interviews:KURT VON EMSTER - MPM CAPITAL LPJuly 19, 2004Kurt Von Emster - Mpm Capital LpApril 28, 2003Kurt Von Emster - Mpm Capital LpFebruary 25, 2002Biotechnology Stocks : Kurt  Von Emster - Franklin Advisers IncMay 29, 2000Biotechnology Stocks : Kurt Von Emster - Franklin Advisers IncNovember 01, 1999Biotechnology Stocks : Kurt Von Emster - Franklin Advisors IncSeptember 28, 1998







CartLatest NewsJames Abate of Centre Asset Management Sees Consumer Demand Driving New Stock HighsMalcolm E. Polley of Stewart Capital and How to Play the Health Care StocksTimothy Biltz, CEO of Lumos Networks Identifies the Key Component for Future 5G NetworksThe Wall Street Transcript is a completely unique resource for investors and business researchers.Over 20,000 CEO, Equity Analyst and Money Manager InterviewsSubscribe now!Sign Up For Newsletter Weekly email with New In-Depth Interviews


Email: 



Most Popular InterviewsDelivering Long-Term Results with a Risk-Managed Growth FundJames A. Abate Published July 20, 2017 in Investing StrategiesCompanies covered: AMAT JNJ COH RL COG NVDA ADBE ATVI KLAC AMZN NFLX GOOG FB GLW MU 005930 000660 WFM JWN CMG GPS EQT RICE SPLS Buy ($25)Finding Investments with Favorable Risk and Reward OpportunitiesHenry  Beukema Published July 19, 2017 in Investing StrategiesCompanies covered: ORCL MSFT NSRGY AMZN WFM LRLCY AGN LNR Buy ($25)Better Returns and Lower Risk in the Midcap SpaceMalcolm E. Polley Published July 18, 2017 in Investing StrategiesCompanies covered: PRAA HURN FII FL NKE AMZN WFM WBA RAD Buy ($25)Most Popular ReportsWireless Communications & Telecom Published July 14, 2017Buy ($175)Investing Strategies Published July 11, 2017Buy ($175)Investing Strategies Published June 30, 2017Buy ($175) 






Top Company Interviews






Register for a Free Account to gain greater access to
            The Wall Street Transcript right now




CEO INTERVIEWSInterview with the President and CEO: Lumos Networks Corp. (NASDAQ:LMOS)Interview with the Corporate VP of Business Development, Strategy and Investor Relations: DSP Group, Inc. (NASDAQ:DSPG)Interview with the CEO and Director: Tactile Systems Technology, Inc. (NASDAQ:TCMD) 

SECTOR ROUNDTABLESNatural Gas Weighs Heavy On E&P Near-Term ProspectsRoundtable Forum:optimism Despite Uncertainty In For-profit EducationRoundtable Forum:a Shift In Focus To Natural Gas From Oil 

MONEY MANAGER INTERVIEWSDelivering Long-Term Results with a Risk-Managed Growth FundFinding Investments with Favorable Risk and Reward OpportunitiesBetter Returns and Lower Risk in the Midcap Space 

ANALYST INTERVIEWSAnalyzing the Secular Drivers Within Communications Infrastructure and TelecomSatellite Companies Benefiting from Growth in Data TrafficIncreased Focus on Content as Consumers Shift to Digital Consumption 




Subscribe Today!







                Since 1963
                © The Wall Street Transcript 1997-2016
Terms and Conditions
Privacy Policy  
            





https://www.twst.com/wp-admin/admin-ajax.php

Pin It on Pinterest





































Share This





Twitter





Facebook





Google+





Gmail





LinkedIn








































×





Join now for free!
Already a member?






First Name 





Last Name 





Email address *








Create new account
 


or create an account with a social network.

Join with Facebook


Join with Twitter


Join with Google








Username or Email address: *





Password: *






LoginJoin now! | Forgot password?
 


or login using a social network


Log in with Facebook


Log in with Twitter


Log in with Google














Kurt and Beth von Emster | First Republic Bank



















































×
Secure Sign In



                        Banking Online
                        



                        Banking Online
                        



                        Corporate Online
                        



                        Corporate Online
                        



                        Brokerage Online
                        



                        Trust Online
                        



                        Foreign Exchange Online
                        



                        Eagle Invest
                        



                        Banking Online Full Site
                        



                        Corporate Online Full Site
                        




Search

 


Search
 Cancel










Also Find Us on:





























x
Notice: This website is not optimized for your current browser.

Please take action to ensure continued access to FirstRepublic.com. We will be discontinuing service to older web browsers with outdated security settings. Please update to the latest version of Google Chrome, Internet Explorer, Safari or Firefox. For assistance, please call (888) 372-4891.
















At First Republic, the home loan experience was easy. At our other bank, we were totally anonymous.
At First Republic, the home loan experience was easy. At our other bank, we were totally anonymous.

Kurt and Beth von Emster
|

                                        Northern California, Peninsula/Silicon Valley
                                    
Clients of First Republic Bank Since '12









Kurt and Beth von Emster focus their careers on life sciences private equity. After hearing a friend say that the smartest thing he ever did was to bank with First Republic, they decided to move over their accounts. The couple finds that First Republic treats them as real people, with real lives, and the ease of First Republic’s online banking services and stress-free processes make their lives a little less hectic.

                            Pictured Above
                            Kurt von Emster, Managing Partner, Abingworth
Beth von Emster, Attorney
                        





Related Testimonials










Candace Neal













Richard and Susan Kramer













Yasmin Naghash








See All













Share



Email


Twitter


Facebook


LinkedIn








Recent Articles



Five Signs You’re Ready to Buy Your First Home




Pass on Your Assets Wisely: How to Choose the Right Beneficiaries




Passing Along an Inheritance? Five Tips for Preparing Your Heirs









 All Testimonials











Get Started Today
Our Relationship Managers are ready to tailor financial solutions to suit your individual needs.


Give us a call

Give us a call

Our Relationship Managers are ready to tailor financial solutions to suit your individual needs.


(855) 886-4824







Have us contact you

Have us contact you

If you'd prefer to have us reach out to you, complete the online form and we will be in touch.


Continue to form






Find an office near you

Find an office near you

We welcome you to visit our locations. Use our locator to find one of our offices near you.


Find an office































Kurt von Emster CPA, CFA: Executive Profile & Biography - Bloomberg










































  





















































































July 23, 2017 5:59 PM ET
Capital Markets

Company Overview of Abingworth LLP



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Kurt   von Emster CPA, CFAManaging Partner, Abingworth LLPAgeTotal Calculated CompensationThis person is connected to 3 Board Members in 3 different organizations across 7 different industries.See Board Relationships50--
Background

		Mr. Kurt von Emster, CPA, CFA serves as Managing Partner at Abingworth LLP. Mr. von Emster works with the team to help source and manage deals in early-stage and late-stage venture capital, venture growth, Pharmaceutical co-development and public market investments including VIPEs (Venture Investments in Public Equities). His role is to identify, invest and provide support for portfolio companies. Mr. von Emster served as its Joint Managing Partner at Abingworth LLP ... since July 7, 2015 and its Partner since January 5, 2015. He joined Abingworth LLP in January 2015. Mr. von Emster was Managing Director, Partner and Portfolio Manager of MPM BioEquities Fund, L.P.; MPM BioVentures III, L.P. and MPM BioVentures IV, L.P. He was the Managing Director, Managing Partner and Partner at venBio LLC which he co-founded in 2009. Mr. von Emster worked with the Franklin Templeton Group, where Mr. von Emster served as a Vice President and Portfolio Manager for 11 years. In his tenure at Franklin, he was responsible for building the health care group and was responsible for conceiving and developing seven different life science investment products for Franklin. At Franklin Templeton Group, Mr. von Emster managed over $2 billion in health and biotech funds and was responsible for building its health care group. He began his career as a Biotechnology and Healthcare Analyst and Portfolio Manager at Franklin Templeton. Mr. von Emster was also responsible for conceiving and developing seven different life science investment products for Franklin Templeton Group. Within these funds, he introduced innovative trading strategies, including short selling, which contributed to the funds' stellar performance. Mr. von Emster served as Managing Director at MPM Capital from 2001 to 2009 and its Partner and Portfolio Manager. He also served as a General Partner at MPM Capital. Mr. von Emster was responsible for seven private company investments in his career. He serves as an Interim Chairman of SutroVax, Inc. since July 23, 2015 and also serves as a Director. He has been an Independent Director of Cymabay Therapeutics, Inc. since April 2009. Mr. von Emster was an Additional Director of Cytos Biotechnology AG since May 2012. He has been an Independent Director of CRISPR Therapeutics AG since April 2015. Mr. von Emster served as an Independent Director of Aurinia Pharmaceuticals Inc. from February 14, 2014 to March 6, 2015. He served as a Director of Pernix Sleep, Inc. since August 2005. Mr. von Emster was a Director at Facet and Somaxon Pharmaceuticals. He was an Observer of Acceleron Pharmaceuticals. Mr. von Emster was a Director of AbbVie Biotherapeutics Inc. since February 24, 2009. He was a Member of the Board of Directors of Kesios Therapeutics Limited. Mr. von Emster is special guest on Wall Street Week with Louis Rukeyser and is a regular guest on CNBC and CNN's MoneyLine. He has 25 years of experience in life science investment in both private and public companies. Mr. von Emster is institutional biotechnology and health care Analyst and Portfolio Manager for over 20 years. He holds the Chartered Financial Analyst designation (CFA Institute). Mr. von Emster holds Bachelor of Science degree from the University of California at Santa Barbara in Business and Economics.Read Full Background




Corporate Headquarters
38 Jermyn StreetLondon, Greater London SW1Y 6DNUnited KingdomPhone: 44 20 7534 1500Fax: 44 20 7287 0480
Board Members Memberships
Interim ChairmanSutroVax, Inc.2009-PresentIndependent DirectorCymabay Therapeutics, Inc.2015-PresentIndependent DirectorCRISPR Therapeutics AG
Education
BS University of California, Santa Barbara
Other Affiliations
MPM CapitalCymabay Therapeutics, Inc.Cytos Biotechnology AGAurinia Pharmaceuticals Inc.MPM BioVentures III, L.P.MPM BioEquities Fund, L.P.MPM BioVentures IV, L.P.University of California, Santa BarbaraPernix Sleep, Inc.AbbVie Biotherapeutics Inc.venBio LLCKesios Therapeutics LimitedCRISPR Therapeutics AGSutroVax, Inc.


Annual Compensation
				There is no Annual Compensation data available.
				Stocks Options
				There is no Stock Options data available.
				Total Compensation
				There is no Total Compensation data available.
			



Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONThere is no Competitor Compensation data available.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Abingworth LLP, please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close
































Kurt Von Emster - Mpm Capital Lp - The Wall Street Transcript
















































 






































Healthcare >> Money Manager Interviews >> April 28, 2003 Kurt Von Emster – Mpm Capital Lp
KURT VON EMSTER joined MPM Capital, LP, in November 2000 to extend their
healthcare investment presence into the public markets. He is a General
Partner of the MPM BioEquities Fund and manages several funds for MPM
Advisors. He spent 11 years with Franklin Templeton Group as a Vice
President and Portfolio Manager. At Franklin, Mr. von Emster managed
over $2 billion in health and biotech funds, including the Franklin
Biotechnology Discovery Fund and the Franklin Global Health Care Fund.
Mr. von Emster holds the Chartered Financial Analyst designation, is a
member of the Association for Investment Management and Research, and is
a member of the Security Analysts of San Francisco. Mr. von Emster
earned a degree from the University of California Santa Barbara in
Business and Economics. Profile


TWST: Can you bring us up-to-date on MPM Capital and yourBioEquities Fund?Mr. von Emster: The MPM BioEquities Fund is a predominantly long-biased biotechnology fund. The Fund is invested
    

Join for free to read a longer excerpt or purchase this article

Already a member? Login here 









CartLatest NewsJames Abate of Centre Asset Management Sees Consumer Demand Driving New Stock HighsMalcolm E. Polley of Stewart Capital and How to Play the Health Care StocksTimothy Biltz, CEO of Lumos Networks Identifies the Key Component for Future 5G NetworksThe Wall Street Transcript is a completely unique resource for investors and business researchers.Over 20,000 CEO, Equity Analyst and Money Manager InterviewsSubscribe now!Sign Up For Newsletter Weekly email with New In-Depth Interviews


Email: 



Most Popular InterviewsDelivering Long-Term Results with a Risk-Managed Growth FundJames A. Abate Published July 20, 2017 in Investing StrategiesCompanies covered: AMAT JNJ COH RL COG NVDA ADBE ATVI KLAC AMZN NFLX GOOG FB GLW MU 005930 000660 WFM JWN CMG GPS EQT RICE SPLS Buy ($25)Finding Investments with Favorable Risk and Reward OpportunitiesHenry  Beukema Published July 19, 2017 in Investing StrategiesCompanies covered: ORCL MSFT NSRGY AMZN WFM LRLCY AGN LNR Buy ($25)Better Returns and Lower Risk in the Midcap SpaceMalcolm E. Polley Published July 18, 2017 in Investing StrategiesCompanies covered: PRAA HURN FII FL NKE AMZN WFM WBA RAD Buy ($25)Most Popular ReportsWireless Communications & Telecom Published July 14, 2017Buy ($175)Investing Strategies Published July 11, 2017Buy ($175)Investing Strategies Published June 30, 2017Buy ($175) 






Top Company Interviews






Register for a Free Account to gain greater access to
            The Wall Street Transcript right now




CEO INTERVIEWSInterview with the President and CEO: Lumos Networks Corp. (NASDAQ:LMOS)Interview with the Corporate VP of Business Development, Strategy and Investor Relations: DSP Group, Inc. (NASDAQ:DSPG)Interview with the CEO and Director: Tactile Systems Technology, Inc. (NASDAQ:TCMD) 

SECTOR ROUNDTABLESNatural Gas Weighs Heavy On E&P Near-Term ProspectsRoundtable Forum:optimism Despite Uncertainty In For-profit EducationRoundtable Forum:a Shift In Focus To Natural Gas From Oil 

MONEY MANAGER INTERVIEWSDelivering Long-Term Results with a Risk-Managed Growth FundFinding Investments with Favorable Risk and Reward OpportunitiesBetter Returns and Lower Risk in the Midcap Space 

ANALYST INTERVIEWSAnalyzing the Secular Drivers Within Communications Infrastructure and TelecomSatellite Companies Benefiting from Growth in Data TrafficIncreased Focus on Content as Consumers Shift to Digital Consumption 




Subscribe Today!







                Since 1963
                © The Wall Street Transcript 1997-2016
Terms and Conditions
Privacy Policy  
            





https://www.twst.com/wp-admin/admin-ajax.php

Pin It on Pinterest





































Share This





Twitter





Facebook





Google+





Gmail





LinkedIn








































×





Join now for free!
Already a member?






First Name 





Last Name 





Email address *








Create new account
 


or create an account with a social network.

Join with Facebook


Join with Twitter


Join with Google








Username or Email address: *





Password: *






LoginJoin now! | Forgot password?
 


or login using a social network


Log in with Facebook


Log in with Twitter


Log in with Google


















Abingworth - Kurt von Emster





















 








Sign-in...






Search: 










About




About Us




Our Team 




Transatlantic Reach




Funds






Strategy




Our Strategy




Venture Capital




Clinical Co‑development




VIPEs




Public Markets






Portfolio




Venture Portfolio




Case Studies






Media




Recent News




Film








Contact




Contact Us




Send Us Your Proposal











Kurt von Emster


 BACK





Managing Partner

Location: 
Menlo Park, USA
Expertise: Venture Capital, Public Markets, Pharmaceutical co-development, VIPEs

Kurt joined Abingworth in January 2015 bringing 25 years of experience in life science investment in both private and public companies. He holds board positions at the Abingworth portfolio companies CRISPR Therapeutics and SutroVax. In addition, he is on the board of CymaBay.
Kurt began his career as a Biotechnology and Healthcare Analyst and Portfolio Manager at Franklin Templeton. He then became a General Partner at MPM Capital. In 2009, he co-founded venBio, a US healthcare investment firm and most recently was a Partner in the San Francisco office. Kurt holds a Bachelor of Arts in Business and Economics. He is based in Menlo Park.








Administrative Support
Gwen Kinard
Tel: + 650 926 0600
gwen@abingworth.com
























HOME
TERMS OF USE
PRIVACY POLICY
FPCS CODE


Copyright Abingworth 2017
























Home

About Us


About Us
Our Team 
Transatlantic Reach
Funds


Strategy


Our Strategy
Venture Capital
Clinical Co‑development
VIPEs
Public Markets


Portfolio


Portfolio Companies
Case Studies


Media Centre


Recent News
Archived News
Film


Contact 


Contact Us
Send Us Your Proposal








Kurt von Emster


Managing Partner
Location:
Menlo Park, USA
Expertise: Venture Capital, Public Markets, Pharmaceutical co-development, VIPEs



Kurt joined Abingworth in January 2015 bringing 25 years of experience in life science investment in both private and public companies. He holds board positions at the Abingworth portfolio companies CRISPR Therapeutics and SutroVax. In addition, he is on the board of CymaBay.
Kurt began his career as a Biotechnology and Healthcare Analyst and Portfolio Manager at Franklin Templeton. He then became a General Partner at MPM Capital. In 2009, he co-founded venBio, a US healthcare investment firm and most recently was a Partner in the San Francisco office. Kurt holds a Bachelor of Arts in Business and Economics. He is based in Menlo Park.








Administrative Support
Gwen Kinard
Tel: + 650 926 0600
gwen@abingworth.com








 






DISCLAIMER PRIVACY POLICY FPCS CODE
Copyright Abingworth 2017











Kurt  Von Emster - Belmont, CA | Intelius



























Sign In



We found Kurt  Von Emster in Belmont, CA


Kurt  Von Emster

                                                                           Intelius found that Kurt  Von Emster  is  a male between 50 and 50 years old from Belmont, CA.  We have connected them to
                7 addresses,
                4 phones,
                and 3 relatives or associates.
         





Also Known As

Kurt Konrad Von Emster
Kurt M Vonemster
K M Von Emster
Kurt E Vonemster
Kurt Von Emster


Get Report Now

Age

Kurt  Von Emster is in his 50s

Kurt Has Lived In

Belmont, CA
South San Francisco, CA
San Diego, CA

Kurt's Relatives

Elizabeth Vonemster
F von E
Konrad Vonemster







Kurt  Von Emster



Zodiac SignGemini



GenderMale



Professional Status
Member of the Board of Directors at Somaxon Pharmaceuticals , Inc.



Get Report Now










Want to know more about Kurt? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Kurt, or use our people search engine to find others.
Get Background Check on Kurt  Von Emster
Get a Criminal Check on Kurt  Von Emster
Get a Public Record Report on Kurt  Von Emster
Get a People Search Report on Kurt  Von Emster


Kurt  Von Emster's Contact Information
Known Cities Lived In
Find out where Kurt  Von Emster has lived as well as Kurt  Von Emster's phone numbers and email addresses.




Kurt  Von Emster Has Lived in 2 States
California Address for Kurt  Von Emster


1647 R****** A** 

Belmont, CA


Has Lived In

Belmont, CA
South San Francisco, CA


Get Full Address Report










Phone Numbers Associated with Kurt  Von Emster

(415) ***-**** - San Francisco, CA 
(800) ***-**** - San Mateo, CA 
(650) ***-**** - Belmont, CA 


Get Full Phone Report



Email Addresses Associated with Kurt  Von Emster

k********r@***.com
k********r@***.com
k********r@***.com


Get Email Report




Kurt  Von Emster's Professional Information
Information regarding Kurt  Von Emster's professional history.  Find out previous places Kurt  Von Emster has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Kurt  Von Emster Has Worked at 4 Places
Company: Somaxon Pharmaceuticals , Inc.
               Title: Member of the Board of Directors
Company: Venbio
               Title: Managing Director
Kurt  Von Emster's Experience
Title: Member of the Board of Directors
               Company: Somaxon Pharmaceuticals , Inc.
Job Details
               Company Size: Less than $1 mil - Employee Range: Less than 25
Title: Managing Director
               Company: Venbio
Job Details
               venBio is a next-generation investment firm, partnering with life science leaders to invest in novel medicines and game-changing technologies in the advancement of health care. venBio was established with a vision to create a new model of life sciences investing. venBio believes that integrating all life sciences stake-holders is critical to success. Our team of multidisciplinary global experts partner with biotechnology, life sciences and clinical trial corporate leaders in a new investment paradigm. venBio manages private equity funds backed by leading life sciences companies and qualified financial investors. Our investment focus is on clinical stage private and public small cap companies with a therapeutic product, and to a lesser extent medical technologies that enable better care for patients. venBio continues to develop new products for today's changing global environment. Our focus is to deliver financial, ethical and strategic returns. The intersection of all three in the venn diagram is the biological center of our universe, and the foundation of our name and logo, venBio. venBio is a life sciences investment firm, partnering with industry leaders to build and invest in game-changing medicines and technologies with a focus on novel therapeutics for unmet medical needs. With a presence in San Francisco, CA and New York, NY, venBio manages both a long / short equity strategy along with venture capital funds which are backed by leading life sciences companies and qualified financial investors.
Additional Professional Information on Kurt  Von Emster

 See Kurt  Von Emster's LinkedIn Profile



Kurt  Von Emster's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Kurt  Von Emster


Kurt  Von Emster's known Social Networks And Potential Email Matches

Find all of Kurt  Von Emster's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Kurt Von Emster
Username Matches

                  KurtVon Emster
                  Von EmsterKurt
                  Kurt.Von Emster
                  Von Emster.Kurt
                  Kurt_Von Emster
                  Von Emster_Kurt
                  Kurt-Von Emster
                  Von Emster-Kurt
                  KVon Emster
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
K Von Emster







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.
































 



 Abingworth Appoints Kurt von Emster as a Partner in Menlo Park 
         










    









 






 











 









Abingworth Appoints Kurt von Emster as a Partner in Menlo Park

Dec 05, 2014, 04:00 ET
		  		  					
						 from   Abingworth 











 
















































 

 




















 


LONDON, December 5, 2014 /PRNewswire/ --
Abingworth, the international investment group dedicated to life sciences and healthcare, today announced the appointment of Kurt von Emster as a Partner effective 5th January. Kurt will be based in Abingworth's Menlo Park office where he will work with the team to help source and manage deals in early-stage and late-stage venture capital, venture growth and public market investments including VIPEs (Venture Investments in Public Equities).
Kurt brings 25 years of experience in the life sciences sector where he was initially a biotechnology and healthcare analyst and portfolio manager at Franklin Templeton. He then became a General Partner at MPM Capital. In 2009, Kurt co-founded venBio, a US healthcare investment firm and most recently was a Partner in the San Francisco office. Kurt holds a Bachelor of Science in Business and Economics.
"We are delighted to welcome Kurt to our team," said Stephen Bunting, Managing Partner. "Kurt is a well known figure in the life sciences investment space both in public and private investment. He will be a great addition to the team and will add significantly to our presence in the US."
"I am excited to be joining a recognised global leader in healthcare investing such as Abingworth, with its transatlantic presence and history spanning more than 40 years in venture capital," said Kurt von Emster. "I believe the multifaceted platform of investment opportunities Abingworth offers is impressive and I look forward to building upon this success."
Notes for Editors 
About Abingworth 
Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sector. Founded in 1973, Abingworth has a lengthy track record of backing market leading companies. Abingworth has a specialist team of 28 professionals with a broad range of skill sets and access to an extensive network of industry contacts. Abingworth has funds under management of over $1.25 billion and offices in London, Menlo Park (California) and Boston.
To date, Abingworth has raised 15 funds including ten funds dedicated to investment in life sciences and healthcare. Successful investments have included Ablynx, Algeta, Alkermes, Alnylam, Amarin, Avila Therapeutics, Clovis Oncology, Fovea, Geltex, Genetic Therapy, Gilead, IDEC Pharmaceuticals, Intellikine, Novexel, Pharmion, PowderMed and Solexa. For a full list of Abingworth's portfolio companies please visit the website: http://www.abingworth.com
 SOURCE  Abingworth  




  

 View Table Fullscreen 




  View Table Fullscreen 





Journalists and Bloggers
The news you need, when you need it.
 
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.
LEARN MORE




 

 
 



















































  











Jul 07, 2015, 04:00 ET
Preview: Abingworth Appoints Tim Haines and Kurt von Emster as Joint Managing Partners













Jul 10, 2014, 04:00 ET
Preview: Abingworth Promotes Ken Haas and Vin Miles to Partners






My News


  Release contains wide tables.	  View fullscreen.





Looking to send a news release with PR Newswire?
Take advantage of the world's leading distribution platform.
Sign up to get started
Request more information
Have an account? Log In

 















Search











Searching for your content...









Advanced Search












































 


 


























Kurt von Emster – New England Venture Capital Association












































Skip to banner
Skip to main navigation
Skip to main content









Menu








Investor Profile

List Firms
Search Investors



 

Sectors

Biotechnology
Diabetes
Health Care















Kurt von Emster
Managing Partner


          Abingworth        

Kurt von Emster, CFA is a co-founder and Managing Partner of venBio. Mr. von Emster has been an institutional biotechnology and health care analyst and portfolio manager for 22 years. 
He is a member of the board of directors of Cytos AG and CymaBay Therapeutics and ., a former member of the board of Facet Biotech Corporation (sold to Abbott Laboratories in 2010) and Somaxon Pharmaceuticals (sold to Pernix Therapeutics in 2013), and a former board observer of Acceleron Pharma. 
Mr. von Emster’s investment career started in 1989 at Franklin Templeton where he founded and managed several health and biotechnology funds in the 1990s, each achieving a 5-star Morningstar ranking. In 2000, he was managing over $2B in biotech and health care funds for Franklin Templeton. 
In 2001, Mr. von Emster became a General Partner at MPM Capital, a leading biotechnology private equity firm, and launched the MPM BioEquities Fund, a cross over public and private biotechnology hedge fund. He was the portfolio manager of this fund from inception in 2001 until his departure in 2009. 
He also co-founded the MPM Biogen Idec Strategic Fund during his tenure at MPM. Mr. von Emster is based in venBio’s San Francisco office.

Visit CrunchBase to update this profile.




Stay Up to Date on Events Keep in touch and never miss out on a Boston area event!
Sign Up
Meet Our Sponsors Supporting Sponsors








Major Sponsors








Data Sponsor



About Our Sponsors
Recent Tweets







2d
NEVCA
@NewEnglandVC


                      RT @VentureApp: ICYMI this morning, @jodyarose & @sliggity discussed steps community & @NewEnglandVC take to fix misogyny in  tech https://… 








2d
NEVCA
@NewEnglandVC


                      Join @BostonNewTech #BNT80 with 6 exciting New #Tech product demos 8/15 6pm at @LogMeIn https://t.co/LxEtoSrqyX #Boston #MA #startups 








2d
NEVCA
@NewEnglandVC


                      Have you heard about the @HubSpot for startups program?  Great opp for the community.  Learn more below. https://t.co/PRleOoUT4P 



Follow @NewEnglandVC 
Keep In Touch 









Email Address*



First Name*



Last Name*



Company/School*

 
				* = required field			

								I am a							


VC


Entrepreneur


Student


Community Member







				powered by MailChimp!
			









Don’t miss out. Stay up to date on all events and information around Boston and the NEVCA!



Keep in Touch

















News on Kurt von Emster


























































                      NEWS HOME
                    

Advertising
Board and Executive Moves
Energy
Health Care
Hedge Funds
M & A
Private Equity
Technology















                                Person                            


                                    Kurt von Emster                                    ▼





                                Topic                            


                                    All Topics                                    ▼








Organizations

                                Find news about organizations
                            





Alumni

                                Find news on alumni of any org
                            





Industries

                                Find news on a particular market
                            





Your Contacts

                                Find news on your contacts
                            








Sign up for free daily alerts on this feed:











By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions


















Follow




                            Change Feed
                        


Kurt von Emster











Kesios Therapeutics raises 19 mln pounds in Series A funding 


                                December 2, 2015                                 • 
                                peHUB                            


                                  ... myeloma and other cancers. Kate Bingham of SV Life Sciences and Kurt von Emster of Abingworth joined the Kesios board. Press Release Kesios Therapeutics Ltd ...
                                









Dr. Shelley Chu joins Abingworth 


                                October 19, 2015                                 • 
                                peHUB                            


                                  ... “We are delighted to welcome Shelley to our global team,” said Kurt von Emster, Managing Partner. “Her extensive venture capital experience and strategic corporate development ...
                                









SutroVax raises $22 million in Series A


                                July 23, 2015                                 • 
                                PR Newswire                            


                                  ... talented team at SutroVax and this prestigious group of co-investors," commented Kurt von Emster, Managing Partner of Abingworth. As part of the financing, Kurt von ...
                                









CTI Life Sciences invests in $22 mln Series A funding of SutroVax 


                                July 23, 2015                                 • 
                                peHUB                            


                                  ... talented team at SutroVax and this prestigious group of co-investors,” commented Kurt von Emster, Managing Partner of Abingworth. As part of the financing, Kurt von ...
                                









Abingworth Appoints Tim Haines and Kurt von Emster as Joint Managing Partners


                                July 7, 2015                                 • 
                                PR Newswire                            


                                  ... to life sciences and healthcare, today announced that Tim Haines and Kurt von Emster, have been appointed as joint Managing Partners of Abingworth. Stephen Bunting, ...
                                









CRISPR Therapeutics Raises Additional $64 Million to Translate Breakthrough CRISPR-Cas9 Technology into Next Generation Therapies for Patients


                                April 29, 2015                                 • 
                                Business Wire                            


                                  ... Board of Directors. Simeon George, SR One, Ali Behbahani, NEA, and Kurt von Emster, Abingworth, will be joining Brad Bolzon, Tom Woiwode, and Chief Executive ...
                                









Aurinia Announces Change to Its Board of Directors


                                March 6, 2015                                 • 
                                Business Wire                            


                                  ... Inc. ("Aurinia" or the "Company") (NASDAQ:AUPH / TSX:AUP) today announced that Mr. Kurt von Emster has tendered his resignation as a member of the Aurinia ...
                                









The JP Morgan mood: Damn the biotech valuations and full speed ahead in 2015


                                January 14, 2015                                 • 
                                FierceBiotech                            


                                  ... is laying out the smorgasbord. "You're always in a bubble" in biotech,Kurt von Emsterurt von Emster told several hundred execs at FierceBiotech's executive breakfast this ...
                                









FierceBiotech Executive Event: Is there more room to boom in biotech in 2015?


                                January 13, 2015                                 • 
                                FierceBiotech                            


                                  ... Chaudhary, managing director and head of capital markets at Leerink; and Kurt von Emster, partner at Abingworth. Watch the video Get the audio version ...
                                









Panel: How to understand the long biotech boom?


                                December 7, 2014                                 • 
                                FierceBiotech                            


                                  ... in biotech in 2015? A recent addition to the panel is Kurt von Emster, who will start in January as a partner at venture firm ...
                                









Abingworth Appoints Kurt von Emster as a Partner in Menlo Park


                                December 5, 2014                                 • 
                                PR Newswire                            


                                  ... Abingworth Appoints Kurt von Emster as a Partner in Menlo Park. LONDON, December 5, 2014 /PRNewswire/ ...
                                









Cytos Biotechnology Ltd Reports Second Quarter 2013 Financial Results and Recent Developments


                                August 6, 2013                                 • 
                                PR Newswire                            


                                  ... 2015, as well as the re-election of Dr. Christian Itin and Kurt von Emster as members of the Board of Directors. Financial Results Three-month period ...
                                







Related News Feeds






Abingworth Management Ltd.







Private Equity & Venture Capital







Board and Executive Moves in Private Equity & Venture Capital







Alumni of University of California - Santa Barbara

























































































































Email







LinkedIn







Facebook







Google+







Tweet







Reddit





Permalink



 






Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!


Start My Free Trial  ➤










 Industry:




 Select a Topic:



 Keyword:



Go  ➤









 Find an Organization:






 Select a Topic:




 Keyword:




Go  ➤









 Find a Person:






 Select a Topic:




 Keyword:




Go  ➤









 Name of a School:







 Or Name of an Organization:









 Select a Topic:




 Keyword:




Go  ➤








Thank you. You are now subscribed.Please wait for the page to refresh...










You are now subscribed to this feed.










You have unsubscribed to this feed.










Thank you. You can now subscribe to more RelSci news feeds.










 To subscribe to more than one feed, please enter a password.




 Please confirm your password



Go  ➤








You've found a premium RelSci Pro feature!



Follow News On Your Contacts

Upgrade to RelSci Pro now to easily sync your contacts and stay in the know on the news about the people important to you.


Start My Free Trial  ➤

Still not convinced? Check out our full listing of features here.



Not Now








You've found a premium RelSci Pro feature!



Search News On Keywords

Curate your news even further with the ability to filter feeds based on specific keywords mentioned in the articles.


Start My Free Trial  ➤

Still not convinced? Check out our full listing of features here.



Not Now













Industries

                        Find news on a particular market
                    





People

                        Find news about people
                    





Organizations

                        Find news about organizations
                    





Alumni

                        Find news on alumni of any org
                    





Your Contacts

                        Find news on your contacts
                    












                Free Daily Alerts
            


                Sign up for free daily alerts on this feed
            




Sign Up ➤

                    By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions




                Already have an account?  Click here to login.















Are you a RelSci Pro Subscriber?

Login to RelSci Pro 
                        ➤


Not a Pro Subscriber? Log in here to manage your alerts









 Keep me signed in.
        

Login  ➤



        Forgot your Password?
    

























 I have read the LexisNexis terms & conditions




Sign Me Up  ➤













